Effect of Superba Krill on Inflammation in Patients With Coronary Artery Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01092793

Enrollment

Registered

2010-03-25

Start date

2010-02-28

Completion date

2012-01-31

Last updated

2023-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable Atherosclerotic Coronary Disease

Keywords

Fish oil, Krill, CAD

Brief summary

Atherosclerotic coronary heart disease is a condition thought to involve low-grade inflammation. Several reports, clinical and epidemiological, have demonstrated that intake of fish oil may be beneficial in attenuating the inflammatory process. Still, however, there are lacking data in respect to whether differences in composition of various marine oils may influence the inflammatory status differently. The hypothesis of the current study is that extract from the antarctic krill (Euphausia superba) is better than traditional fish oils when compared head-to-head with balanced composition of omega 3 content on inflammatory status.

Interventions

DIETARY_SUPPLEMENTKrill

Encapsulated oil from the antarctic crustacean Krill

DIETARY_SUPPLEMENTFish oil

Encapsulated, raffined cod-oil

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Age: 18-80 years * Sex: Male and female * Stable atherosclerotic coronary heart disease (heart attack \>3 months ago or objectified angina pectoris). * No hospitalization for heart disease last 3 months.

Exclusion criteria

* Unstable heart disease. * Heart failure NYHA class III and IV. * Previous valve and/or aortic surgery * Significant concomitant disease (i.e. diseases with known inflammatory activation - e.g. various autoimmune diseases, chronic infections, significant acute infections three weeks before or during the study, connective tissue disease, arthritis, chronic pulmonary disease or serious liver- or kidney-disease). * Simultaneous involvement in other clinical studies involving intervention. * Planned operation or other invasive procedures (e.g. PCI etc.) during the study period.

Design outcomes

Primary

Measure	Time frame
Inflammatory blood status	8 weeks intervention

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026